Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 574-581 , November 2009

Lapatinib: A competitor or companion to trastuzumab?

  • D. Collins

      Affiliations

    • Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland
    • Corresponding Author InformationCorresponding author. Address: Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, York House, 123 St. Stephens Green, Dublin 2, Ireland. Tel.: +353 14028515.
    • ,
  • A.D.K. Hill

      Affiliations

    • Department of Surgery, Beaumont Hospital, Beaumont Road, Dublin, Ireland
    • ,
  • L. Young

      Affiliations

    • Endocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland

Received 1 March 2009 ,Revised 9 June 2009 ,Accepted 11 June 2009.

References 

  1. Citri A, Skaria KB, Yarden T. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003;99:54–65
  2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  3. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  4. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000;92:1991–1998
  5. Yamauchi H, O’Neill A, Gelman R. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER2/c-neu protein. J Clin Oncol. 1997;15:2518–2525
  6. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003;421:756–760
  7. Vogel CJ, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first line treatment of ERBB2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  8. Smith I, Procter M, Gelber RD, et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer; a randomized controlled trial. Lancet. 2007;369:29–36
  9. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684
  10. Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, de Vries EGE, Rodenhuis S, et al. Predicting early failure after adjuvant chemotherapy in high risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res. 2004;10:4457–4465
  11. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006;11:318–324
  12. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  13. Rusnak DW, Lackey K, Affleck K, et al. The effects of the novel reversible epidermal growth factor/ErbB-2 tyrosine kinase inhibitor GW2016 on the growth of human normal and tumour derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001;1:85–94
  14. Xia W, Mullin RJ, Keith BR, et al. Anti-tumour activity of GW 572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and Akt pathways. Oncogene. 2002;21:6255–6263
  15. DiStefano A, Yap HY, Hortobagyi GN, Blumenschein GR. The natural history of breast cancer patients with brain metastasis. Cancer. 1979;44:1913–1918
  16. Stewart JF, King RJ, Sexton SA, Millis RR, Rubens RD, Hayward JL. Oestrogen receptors, site of metastatic disease and survival in recurrent breast cancer. Eur J Cancer. 1981;17:449–453
  17. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer. 1983;52:2349–2354
  18. Engel J, Enckel R, Aydemir U, et al. Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys. 2003;55:1186–1195
  19. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastasis in patients treated with trastuzumab for metastatic breast cancer. Brit J Cancer. 2004;91:639–643
  20. Weitzen R, Zach L, Kaufman B, et al. High incidence of brain metastasis (BM) in patients on trastuzumab (H) for advanced breast cancer. Proc Am Soc Clin Oncol. 2002;21:31b
  21. Wardley AM, Danson S, Clayton AJ, et al. High incidence of brain metastasis in patients treated with trastuzumab for metastatic breast cancer at a large cancer centre. Proc Am Soc Clin Oncol. 2002;21:61a
  22. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastasis in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972–2977
  23. Heinrich B, Brudler O, Siekiera W, et al. Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol. 2003;22:37
  24. Bria E, Cuppone F, Fornier M, Nistico C, Carlini P, Milella M, et al. Cardiotoxicity and incidence of brain metastasis after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109:231–239
  25. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysis. Breast Cancer Res Treat. 2008;112:533–543
  26. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastasis in patients with HER2-positive breast cancer. J Clin Oncol. 2006;24(18S):503
  27. Lin NU, Dieras V, Paul D, et al. EGF105084, a phase II study of lapatinib for brain metastasis in patients with HER2+ breast cancer following trastuzumab based systemic therapy and cranial radiotherapy. J Clin Oncol. 2007;25(18S):1012
  28. Boccardo F, Kaufman B, Baselga J, et al. Evaluation of lapatinib plus capecitabine in patients with brain metastasis (BM) from HER2+ breast cancer enrolled in Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU). J Clin Oncol. 2008;26(15S):1094
  29. Perez-Soler R. Can rash associated with ERBB1 inhibition be used as a marker of treatment outcome?. Oncology. 2003;17:23–28
  30. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–2648
  31. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–717
  32. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  33. Tan-Chu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy in node positive human epidermal growth factor 2 overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23:7811–7819
  34. Perez EZ, Suman VJ, Davidson NE, et al. Exploratory analysis from NCCTG N9831: do clinical and laboratory characteristics predict cardiac toxicity of trastuzumab when administer as a component of adjuvant therapy?. Breast Cancer Res Treat. 2005;94(Suppl. 1):S96
  35. Slamon D, Eiermann W, Robert NJ, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients. In: Presented at the 2006 San Antonio breast cancer symposium, San Antonio, Texas, December 14–17; 2006.
  36. Joensuu H, Kellolumpu-Lehtinen P-L, Bono P, Alanko T, Katja V, Asola R, et al. for the FinHer Study Investigators Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. NEJM. 2006;354:809–820
  37. Perez EA, Byrne JA, Hammond IW, et al. Cardiac safety experience in 3127 patients treated with lapatinib. Ann Oncol. 2006;17(Suppl. 9):70
  38. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008;83(6):679–686
  39. Geyer CE, Cameron D, Lindquist D, et al. A phase III randomized open label international study comparing lapatinib and capecitabine versus capecitabine in women with refractory advanced or metastatic breast cancer (EGF1000151). N Engl J Med. 2006;355:2733–2743
  40. Burris HA. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist. 2004;9(Suppl. 3):10–15
  41. Blackwell K, Kaplan EH, France SX, et al. A phase II open label multicenter study of lapatinib (GW572016) in patients with metastatic breast cancer that has progressed on trastuzumab-containing regimens. Ann Oncol. 2004;15(Suppl. 3):27
  42. Burstein H, Storniolo AM, Franco S, et al. A phase II open label multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regimens. Ann Oncol. 2004;15(Suppl. 3):27
  43. Gomez HL, Chavez MA, Doval DC, et al. Biomarker results from a phase II randomized study of lapatinib (GW572016) as first-line treatment for patients with Her2 FISH-amplified advanced or metastatic breast cancer. Breast Cancer Res Treat. 2005;94(Suppl. 1):S63
  44. Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. J Clin Oncol. 2005;23(Suppl.):193s
  45. Baselga J, Carbonell X, Castaneda-Sato N-J, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. JCO. 2005;23(10):2162–2171
  46. Nishimura R, Okumura Y, Arima N. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival. Breast cancer. 2008;15:57–64
  47. Kaufman B, Trudeau M, Awada A, Blackwell K, Bachelot T, Salazar V, et al. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study. Lancet Oncol. 2009;10:581–586
  48. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676–3685
  49. Eiermann W on behalf of the International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001;12(1):S57–S62
  50. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659–1672
  51. Di Leo A, Gomez HL, Aziz Z, et al. A Phase III, double blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first line treatment for metatsatic breast cancer. J Clin Oncol. 2008;26(34):5544–5552
  52. Gasparini G, Gion M, Mariani L, Papaldp P, Crivellari D, Filippelli G, et al. Randomized phase II trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat. 2007;101:355–365
  53. Eiermann W on behalf of the International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001;12(1):S57–S62
  54. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23(19):4265–4274
  55. Chu Q, Schwartz G, de Bono J, et al. Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol. 2007;25:3752–3758
  56. Xu L, Song S, Zhu J, Luo R, Li L, Jiao S, et al. Capecitabine and trastuzumab as first-line treatment in patients with HER2-positive metastatic breast cancer (MBC): phase II trial results. Poster #2065 at SABCS 2008.
  57. Wardley A, Antoin-Torres A, Pivot X, et al. Trastuzumab (Herceptin) plus docetaxel with or without capecitabine in patients with HER2-positive advanced/ metastatic breast cancer: first efficacy results from the phase II MO16419 (CHAT) study. Breast Cancer Res Treat. 2006;100(Suppl. 1):2063a
  58. Ishida T, Kiba T, Takeda M, Matsuyama K, Teramukai S, Ishiwata R, et al. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2-overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemother Pharmacol Dec 2008 [Epub ahead of print].
  59. National Cancer Institute Clinical Trials. Phase III randomized study of taxane-based chemotherapy in combination with lapatinib ditosylate versus trastuzumab (Herceptin®) in women with HER2/neu-positive metastatic breast cancer. Accessed at <http://www.cancer.gov/clinicaltrials/CAN-NCIC-MA31>.
  60. ClinicalTrials.gov [website] NCT00374322. Tykerb evaluation after chemotherapy (TEACH): lapatinib versus placebo in women with early-stage breast cancer. Available at <http://www.clinicaltrials.gov/ct/show/NCT00374322>.
  61. Clemens M, Kaufman B, Mackey JR et al. Trastuzumab plus anastrozole may prolong overall survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer: results of a post-hoc analysis from the TAnDEM study. J Clin Oncol; 2007 [abstract 231].
  62. Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second line biological therapy produces durable responses in a subset of HER2-positive and ER positive advanced breast cancers. Breast Cancer Res Treat. 2007;102(1):43–49
  63. Chu Q, Goldstein L, Murray N, et al. A phase I, open label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. J Clin Oncol. 2005;23(Suppl.):192s
  64. Clinical trials.gov. NCT00073528. Study comparing GW572016 and letrozole versus letrozole in subjects with advanced or metastatic breast cancer. Available at: <http://www.clinicaltrials.gov/ct/show/NCT00073528>.
  65. Highlights from: the 2008 San Antonio breast cancer symposium. Clin Breast Cancer 2009: 9 (1): 8–15.
  66. Lan K-H, Lu C-H, Yu D. Mechanisms of trastuzumab resistance and their clinical implications. Ann NY Acad Sci. 2005;1059:70–75
  67. Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth inhibitory activity of trastuzumab (Herceptin®) on SKBR3 breast cancer cells. Int J Cancer. 2004;20(108):334–341
  68. Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase receptor inhibitor ZD1839 (Iressa) inhibits Her2/neu (erbB2) overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001;61:8887–8895
  69. Christianson TA, Doherty JK, Lin YJ, et al. NH2-terminally truncated Her2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 1998;58:5123–5129
  70. Chandarlapaty S, Scaltriti M, Baselga J, Ye Q, Solit D, Norton L, et al. Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not HSP90 inhibitors in models of HER2 amplified breast cancer. J Clin Oncol. 2007;25(18S):10515
  71. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER2-overexpressing and trastuzumab treated breast cancer cells. Cancer Res. 2006;66:1630–1639
  72. Trudeau M, Johnston S, Kaufman B, et al. Lapatinib (Tykerb) monotherapy in patients with recurrent inflammatory breast cancer: clinical activity and biologic predictors of response. Ann Oncol. 2006;17(Suppl. 9):69
  73. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene. 2004;23:646–653
  74. Storniolo AM, Burris HA, Overmoyer B, et al. A phase I open label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with trastuzumab. Breast Cancer Res Treat. 2005;94(Suppl. 1):S64
  75. O’Shaughnessy J, Blackwell KL, Burstein H, et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008;26:1015
  76. ClinicalTrials.gov [website] NCT00367471. Combination of lapatinib with carboplatin, paclitaxel and trastuzumab in metastatic breast cancer. Accessed at <http://clinicaltrials.gov/show/NCT00367471>.
  77. ClinicalTrials.gov [website] NCT00470704. Lapatinib in combination with trastuzumab in patients with HER2-positive, metastatic breast cancer. Accessed at <http://clinicaltrials.gov/show/NCT00470704>.
  78. ClinicalTrials.gov [website] NCT00769470. Docetaxel, carboplatin, and trastuzumab and/or lapatinib in treating women with stage I, stage II, or stage III breast cancer that can be removed by surgery. Accessed at <http://clinicaltrials.gov/show/NCT00769470>.
  79. ClinicalTrials.gov [website] NCT00486668. A study of AC followed by a combination of paclitaxel plus trastuzumab or lapatinib or both given before surgery to patients with operable HER2-positive invasive breast cancer part of the NSABP. Accessed at <http://clinicaltrials.gov/show/NCT00486668>.
  80. ClinicalTrials.gov [website] NCT00272987. ErbB2 overexpressing metastatic breast cancer study using paclitaxel, trastuzumab and lapatinib. Available at <http://www.clinicaltrials.gov/ct/show/NCT00272987>.
  81. ClinicalTrials.gov [website] NCT00490139. ALTTO (adjuvant lapatinib and/or trastuzumab treatment optimisation) study; BIG 2–06/N063D. Accessed at <http://clinicaltrials.gov/show/NCT00490139>.
  82. ClinicalTrials.gov [website] NCT00842998. Efficacy study of single agent trastuzumab or lapatinib to treat HER2-overexpressing breast cancer (HERLAP). Accessed at <http://clinicaltrials.gov/show/NCT00842998>.
  83. ClinicalTrials.gov [website] NCT00553358. Neo ALTTO (neoadjuvant lapatinib and/or trastuzumab treatment optimisation) study. <http://clinicaltrials.gov/ct2/show/NCT00553358>.

PII: S0305-7372(09)00089-9

doi: 10.1016/j.ctrv.2009.06.002

Cancer Treatment Reviews
Volume 35, Issue 7 , Pages 574-581 , November 2009

Article Tools

* Image Usage & Resolution